Pliant Therapeutics, Inc.
PLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001746473
No open-market purchases or sales by Pliant Therapeutics, Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $54.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:09 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 11, 2026 | Mar 3, 2025 | Feb 27, 2024 | Jan 25, 2023 | Feb 28, 2022 |
| Revenue | $0 | $0 | $1.58M | $9.69M | $7.57M |
| Operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M |
| Research and development | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M |
| Selling, general and administrative | $47.2M | $59.1M | $57.9M | $39.9M | $27.6M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Interest expense | – | – | $1.27M | – | – |
| Income tax | $0 | $0 | $0 | $0 | – |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M |
| EPS, basic | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| EPS, diluted | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| Weighted shares, basic | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M |
| Weighted shares, diluted | 61.4M | 60.5M | 58.7M | 42.0M | 35.8M |
| Margins and growth | |||||
| Operating margin | – | – | -11654.7% | -1313.4% | -1288.1% |
| Net margin | – | – | -10211.1% | -1273.3% | -1284.5% |
| Revenue growth, year over year | – | −100.0% | −83.7% | +27.9% | −81.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 11, 2026 | Mar 3, 2025 | Feb 27, 2024 | Jan 25, 2023 | Feb 28, 2022 |
| Cash and equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M |
| Short-term investments | $145.5M | $284.5M | $431.0M | $297.5M | $148.9M |
| Accounts receivable | – | – | $0 | $1.98M | $2.00M |
| Total current assets | $196.4M | $362.3M | $505.5M | $340.3M | $209.4M |
| Property, plant and equipment | $2.94M | $5.53M | $3.57M | $4.49M | $4.61M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Accounts payable | $480.0K | $5.96M | $4.53M | $1.58M | $2.97M |
| Total current liabilities | $16.4M | $33.2M | $28.5M | $23.9M | $16.8M |
| Long-term debt | $0 | $30.2M | $10.1M | $9.93M | – |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Shareholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 11, 2026 | Mar 3, 2025 | Feb 27, 2024 | Jan 25, 2023 | Feb 28, 2022 |
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Capital expenditures | $374.0K | $3.85M | $921.0K | $1.76M | $1.95M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
| Stock-based compensation | $26.2M | $37.6M | $44.5M | $22.6M | $10.4M |
| Investing cash flow | $134.3M | $140.3M | -$127.0M | -$150.2M | $73.7M |
| Financing cash flow | -$31.7M | $23.1M | $274.4M | $226.9M | $2.53M |
| Net change in cash | -$25.7M | $7.95M | $31.0M | -$18.0M | $783.0K |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 2815.4% | 233.3% | 137.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 7, 2026 | 61.9M | +0.9% | SEC |
| May 8, 2026 | 61.9M | +0.9% | SEC |
| Mar 5, 2026 | 61.9M | +1.1% | SEC |
| Nov 1, 2025 | 61.4M | +1.0% | SEC |
| Aug 1, 2025 | 61.4M | +1.0% | SEC |
| May 1, 2025 | 61.4M | +1.8% | SEC |
| Feb 21, 2025 | 61.2M | +1.7% | SEC |
| Nov 1, 2024 | 60.9M | +1.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.